33. Tamaki Y, Araie M, Fukaya Y, Nagahara M, Imamura A, Honda M, et al. Effects of lomerizine, a calcium channel antagonist, on retinal and optic nerve head circulation in rabbits and humans. Invest Ophthalmol Vis Sci 2003; 44(11): 4864-71.

34. Mugellini A, Dobovisek J, Planinc D, Cremonesi G, Fogari R. Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial. Clin Ther 2004; 26(9): 1419-26.

35. Gourine AV, Pernow J, Poputnikov DM, Sjoquist PO. Calcium antagonist clevidipine reduces myocardial reperfusion injury by a mechanism related to bradykinin and nitric oxide. J Cardiovasc Pharmacol 2002; 40(4): 564-70.

36. Punukollu G, Gowda RM, Khan IA, Dogan OM. Delayed presentation of calcium channel antagonist overdose. Am J Ther 2003; 10(2): 132-4.

37. Salhanick SD, Shannon MW. Management of calcium channel antagonist overdose. Drug Saf 2003; 26(2): 65-79.

38. Moreno FL, López OJ, Hernández L. Hiperinsulinemia-euglicemia para el tratamiento de la intoxicación con bloqueadores de los canales de Calcio. Revista MediCiego 2004; 10(Supl 1). [Consultado 22/08/2005]. Disponible en: http://www.cav.sld.cu/centro/Revista/Vol10.Suple1/ T38.htm

39. Patki KC, Greenblatt DJ, von Moltke LL. Ethanol inhibits in-vitro metabolism of nifedipine, triazolam and testosterone in human liver microsomes. J Pharm Pharmacol 2004; 56(8): 963-6.

40. Michalets EL, Williams CR. Drug interactions with cisapride: clinical implications. Clin Pharmacokinet 2000; 39(1): 49-75.

41. Kuschnir E, Acuna E, Sevilla D, Vasquez J, Bendersky M, Resk J, et al. Treatment of patients with essential hypertension. amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg and placebo. Clin Ther 1996; 18(6): 1213-24.

42. Bendersky M, Negri AL, Nolly H, Arnolt M, Re A, Wasserman A. Comparison of amlodipine and enalapril in the treatment of isolated systolic hypertension in the elderly: an open label, randomized, parallel-group study. Curr Therap Res 2002; 63(2): 153-164.

43. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004; 363(9426): 2049-51.

44. Wang JG, Staessen JA. Antihypertensive drug therapy in older patients. Curr Opin Nephrol Hypertens 2001; 10: 263-9.

45. Milberg P, Reinsch N, Osada N, Wasmer K, Monnig G, Stypmann J, et al. Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3. Basic Res Cardiol 2005; 100(4): 365-71.

46. Aiba T, Shimizu W, Inagaki M, Noda T, Miyoshi S, Ding WG, et al. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. J Am Coll Cardiol 2005; 45(2): 300-7.

47. Arya A, Haghjoo M, Emkanjoo Z, Fazelifar AF, Dehghani MR, Heydari A, et al. Comparison of presystolic purkinje and late diastolic potentials for selection of ablation site in idiopathic verapamil sensitive left ventricular tachycardia. J Interv Card Electrophysiol 2004; 11(2): 135-41.

48. Kannankeril PJ, Roden DM, Fish FA. Suppression of bidirectional ventricular tachycardia and unmasking of prolonged QT interval with verapamil in Andersen's syndrome. J Cardiovasc Electrophysiol 2004; 15(1): 119.

49. Cleary-Goldman J, Salva CR, Infeld JI, Robinson JN. Verapamil-sensitive idiopathic left ventricular tachycardia in pregnancy. J Matern Fetal Neonatal Med 2003; 14(2): 132-5.

50. Ogasawara K, Noda A, Yasuda S, Kobayashi M, Yukawa H, Ogawa A. Effect of calcium antagonist on cerebral blood flow and oxygen metabolism in patients with hypertension and chronic major cerebral artery occlusion: a positron emission tomography study. Nucl Med Commun 2003; 24(1): 71-6.

51. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106(19): 2422-7.

52. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al for the CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004; 292(18): 2217-25.

53. Kuschnir E, Castro R, Bendersky M, Sgammini H, Guzman L, Sgarlatta H, et al. Hemodynamic effects of Nitrendipine on systolic ventricular function, diastolic ventricular function and peripheral circulation on essential hypertension. J Cardiovasc Pharmacol 1988; 12 (Suppl 4): 36-44.

54. Kuschnir E, Bendersky M, Resk J, Panart MS, Guzman L, Plotquin Y, et al. Effects of the combination of low-dose nifedipine GITS 20 mg and losartan 50 mg in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 2004; 43(2): 300-5.

55. Franzoni F, Santoro G, Regoli F, Plantinga Y, Femia FR, Carpi A, et al. An in vitro study of the peroxyl and hydroxyl radical scavenging capacity of the calcium antagonist amlodipine. Biomed Pharmacother 2004; 58(8): 423-6.

56. Nebe B, Holzhausen C, Rychly J, Urbaszek W. Impaired mechanisms of leukocyte adhesion in vitro by the calcium channel antagonist mibefradil. Cardiovasc Drugs Ther 2002; 16(3): 183-93.

57. Cantú-Brito C, Rodríguez-Saldaña J, Reynoso-Marenco MT, Marmolejo-Henderson R, Barinagarrementeria-Aldatz F. Factores de riesgo cardiovascular y aterosclerosis carotídea detectada por ultrasonografía. Salud Pública Mex 1999; 41: 452-9.

58. Pobrete R. Marcadores precoces de ateroesclerosis. Rev Chilena de Cirugía 2005; 57(2): 101-8.

59. Shinomiya K, Mizushige K, Fukunaga M, Masugata H, Ohmori K, Kohno M, et al. Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells. J Int Med Res 2004; 32(2): 170-5.

60. Angeli F, Verdecchia P, Reboldi GP, Gattobigio R, Bentivoglio M, Staessen JA, et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens 2004; 17(9): 817-22.

61. Boyer EW, Shannon M. Treatment of calcium-channel-blocker intoxication with insulin infusion. N Engl J Med 2001; 344(22): 1721-2.

62. Nordlander M, Sjoquist PO, Ericsson H, Ryden L. Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev 2004; 22(3): 227-50.

63. Wahed MI, Watanabe K, Ma M, Nakazawa M, Takahashi T, Hasegawa G, et al. Effects of pranidipine, a novel calcium channel antagonist, on the progression of left ventricular dysfunction and remodeling in rats with heart failure. Pharmacology 2004; 72(1): 26-32.

64. Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T. Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol 2004; 43(5): 724-30.

65. Nebe B, Kunz F, Peters A, Rychly J, Noack T, Beck R. Induction of apoptosis by the calcium antagonist mibefradil correlates with depolarization of the membrane potential and decreased integrin expression in human lens epithelial cells. Graefes Arch Clin Exp Ophthalmol 2004; 242(7): 597-604.

66. Wandel C, Kim RB, Guengerich FP, Wood AJ. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab Dispos 2000; 28(8): 895-8.

67. Bohlooli S, Keyhanfar F, Mahmoudian M. Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats. Biopharm Drug Dispos 2004; 25(4): 187-91.

Autores:

Dr. Francisco L. Moreno-Martínez (1),
Dr. Silvio Cepero Franco (2),
Dra. Omaida J. López Bernal (3),
Dra. Marilyn Ramírez Méndez (4),
Luis Monteagudo Lima (5).

1.- Especialista de I y II Grados en Cardiología. Diplomado en Terapia Intensiva de Adultos. Profesor Colaborador de la Universidad Virtual de Salud de Cuba. Cardiocentro “Ernesto Che Guevara”, Santa Clara, Cuba.
2.- Especialista de I y II Grados en Farmacología. Máster en Toxicología Clínica. Profesor Asistente. Facultad de Ciencias Médicas Ciego de Ávila, Unidad Docente Morón, Cuba.
3.- Especialista de I Grado en Anatomía Patológica. Profesora Instructora. Hospital Pediátrico “José Luis Miranda”, Santa Clara, Cuba.
4.- Especialista de I Grado en Anestesiología y Reanimación. Diplomada en Terapia Intensiva de
Adultos. Profesora Instructora. Hospital Universitario Celestino Hernández Robau, Santa Clara,
Cuba.
5.- Especialista de I Grado en Medicina Interna. Diplomado en Terapia Intensiva de Adultos.
Cardiocentro “Ernesto Che Guevara”, Santa Clara, Cuba.